Invokamet is a prescription medication used to treat type 2 diabetes [1]. It combines two active ingredients:
* Metformin: A biguanide that helps control blood sugar levels by reducing glucose production in the liver and decreasing glucose absorption in the intestines [1][2].
* Canagliflozin: An SGLT2 inhibitor that works by causing the kidneys to remove more glucose from the bloodstream [1][2].
Invokamet is typically prescribed when diet and exercise alone, or in combination with other diabetes medications, have not adequately controlled blood sugar [1].
How does Invokamet work to lower blood sugar?
Invokamet targets type 2 diabetes through a dual-action mechanism. Metformin reduces the amount of sugar your liver makes and how much sugar your intestines absorb. Canagliflozin, on the other hand, inhibits the sodium-glucose cotransporter 2 (SGLT2) in the kidneys. This inhibition prevents the reabsorption of glucose, leading to its excretion in the urine [1][2]. This combined approach helps to lower both fasting and post-meal blood glucose levels [1].
What is the difference between Invokamet and Invokamet XR?
The primary difference between Invokamet and Invokamet XR lies in their formulation and dosing schedule. Invokamet XR (extended-release) is designed to release its active ingredients over a longer period, allowing for once-daily dosing [3]. Standard Invokamet is typically taken twice daily [1]. Both formulations contain metformin and canagliflozin.
Can Invokamet be taken with other diabetes medications?
Yes, Invokamet can be prescribed as an add-on therapy for patients whose blood sugar is not adequately controlled with diet and exercise alone or in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin [1]. The decision to combine Invokamet with other agents depends on individual patient needs and treatment goals.
What are the common side effects of Invokamet?
Common side effects associated with Invokamet include [1][4]:
* Nausea
* Vomiting
* Diarrhea
* Abdominal pain
* Loss of appetite
* Metallic taste in the mouth
Serious side effects can occur and include lactic acidosis, urinary tract infections, and ketoacidosis [1].
What is the role of canagliflozin in Invokamet?
Canagliflozin is the SGLT2 inhibitor component of Invokamet. It works in the kidneys to block the reabsorption of glucose. By doing so, it increases the amount of glucose excreted in the urine, which contributes to lowering blood glucose levels [1][2]. This mechanism is distinct from how metformin works in the liver and intestines.
Are there any specific patient populations who should not take Invokamet?
Invokamet is not recommended for individuals with [1]:
* Severe kidney problems
* Metabolic acidosis, including diabetic ketoacidosis
* Known hypersensitivity to metformin or canagliflozin
It is essential for healthcare providers to assess kidney function before initiating and during treatment with Invokamet due to the metformin component.
What are the risks associated with Invokamet?
Significant risks associated with Invokamet include lactic acidosis, a rare but serious complication of metformin accumulation. The risk is higher in patients with kidney impairment, liver disease, or those who consume excessive alcohol [1]. Another risk is diabetic ketoacidosis (DKA), which can occur even with normal blood sugar levels in patients taking SGLT2 inhibitors like canagliflozin [1][4]. Urinary tract infections and yeast infections are also more common in patients taking canagliflozin [1].
How long does it take for Invokamet to work?
The blood sugar-lowering effects of Invokamet can be observed relatively quickly, though it may take several weeks of consistent use to achieve optimal glycemic control [1]. The combined action of metformin and canagliflozin works to reduce glucose levels by different mechanisms.
What is the patent status for Invokamet?
Invokamet is a combination product, and its active ingredients, metformin and canagliflozin, have their own patent landscapes. Metformin, as an older generic drug, has expired patents. Canagliflozin, the active ingredient in Invokana (the brand name for canagliflozin as a single agent), has faced patent challenges and expirations, influencing the market entry of generic versions [5]. Information on specific patent expiry dates for combination products like Invokamet can be tracked through resources like DrugPatentWatch.com [5].
Who manufactures Invokamet?
Invokamet is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
How much does Invokamet cost?
The cost of Invokamet can vary depending on insurance coverage, pharmacy, and whether a generic version is available. While specific pricing information is not provided, prescription drug costs are influenced by factors such as the manufacturer, dosage, and patient assistance programs [1].
What are the alternatives to Invokamet for type 2 diabetes?
Numerous other medications are available for type 2 diabetes management, including other metformin combinations, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, insulin, and other SGLT2 inhibitors [6]. The choice of alternative depends on factors such as efficacy, side effect profiles, cost, and individual patient characteristics.
Sources:
[1] https://www.invokamet.com/
[2] https://www.invokamet.com/how-invokamet-works
[3] https://www.invokametxr.com/
[4] https://www.invokamet.com/important-safety-information
[5] https://drugpatentwatch.com/
[6] https://www.niddk.nih.gov/health-information/diabetes/overview-diabetes/type-2-diabetes/medications